PD1/PDL1轴是侵袭性乳腺癌中一个很有前景的治疗靶点。
The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.
作者信息
Bertucci François, Finetti Pascal, Birnbaum Daniel, Mamessier Emilie
机构信息
Département d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Marseille, France; Département d'Oncologie Médicale, CRCM, Institut Paoli-Calmettes, Marseille, France; Faculté de Médecine, Aix-Marseille Université, Marseille, France.
Département d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725 , Marseille, France.
出版信息
Oncoimmunology. 2015 Aug 31;5(3):e1085148. doi: 10.1080/2162402X.2015.1085148. eCollection 2016 Mar.
Abstract
Analysis of mRNA expression in ∼5,500 breast cancers showed upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with a better pathological response to chemotherapy in these subtypes and IBC. Reactivation of dormant tumor-infiltrating lymphocytes (TILs) by PD1/PDL1-inhibitors represents a promising strategy in these aggressive tumors.
摘要
对约5500例乳腺癌的mRNA表达分析显示，38%的基底样肿瘤和38%的炎性乳腺癌（IBC）出现上调。上调与强烈的细胞毒性局部免疫反应迹象相关，与基底样或三阴性亚型的更好生存率以及这些亚型和IBC对化疗的更好病理反应相关。通过PD1/PDL1抑制剂激活休眠的肿瘤浸润淋巴细胞（TILs）是这些侵袭性肿瘤中有前景的策略。
相似文献
1
The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.
Oncoimmunology. 2015 Aug 31;5(3):e1085148. doi: 10.1080/2162402X.2015.1085148. eCollection 2016 Mar.
2
Prognostic and predictive value of PDL1 expression in breast cancer.
Oncotarget. 2015 Mar 10;6(7):5449-64. doi: 10.18632/oncotarget.3216.
3
PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Cancer Biol Ther. 2018 May 4;19(5):373-380. doi: 10.1080/15384047.2018.1423919. Epub 2018 Feb 16.
4
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
Oncotarget. 2015 May 30;6(15):13506-19. doi: 10.18632/oncotarget.3642.
5
Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
J Clin Pathol. 2017 Oct;70(10):860-867. doi: 10.1136/jclinpath-2016-203990. Epub 2017 Apr 3.
6
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Histopathology. 2016 Jul;69(1):25-34. doi: 10.1111/his.12904. Epub 2016 Jan 13.
7
expression is associated with longer postoperative, survival in adrenocortical carcinoma.
Oncoimmunology. 2019 Aug 28;8(11):e1655362. doi: 10.1080/2162402X.2019.1655362. eCollection 2019.
8
PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Hematol Oncol. 2017 Dec;35(4):487-496. doi: 10.1002/hon.2375. Epub 2016 Dec 13.
9
Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.
Hum Pathol. 2019 Aug;90:60-69. doi: 10.1016/j.humpath.2019.05.007. Epub 2019 May 21.
10
Prognostic value of PDL1 expression in pancreatic cancer.
Oncotarget. 2016 Nov 1;7(44):71198-71210. doi: 10.18632/oncotarget.11685.
引用本文的文献
1
Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity.
Int J Mol Sci. 2023 Oct 10;24(20):15048. doi: 10.3390/ijms242015048.
2
Expression of programmed death-ligand 1, IRF1 and CD8 T lymphocyte infiltration in a primary subset of breast cancer patients in Sudan.
J Taibah Univ Med Sci. 2023 Sep 7;19(1):99-105. doi: 10.1016/j.jtumed.2023.08.006. eCollection 2024 Feb.
3
Aptamer-Based Strategies to Boost Immunotherapy in TNBC.
Cancers (Basel). 2023 Mar 28;15(7):2010. doi: 10.3390/cancers15072010.
4
High Expression of RAI14 in Triple-Negative Breast Cancer Participates in Immune Recruitment and Implies Poor Prognosis Through Bioinformatics Analyses.
Front Pharmacol. 2022 Apr 1;13:809454. doi: 10.3389/fphar.2022.809454. eCollection 2022.
5
Pathological and molecular characteristics of inflammatory breast cancer.
Transl Cancer Res. 2019 Oct;8(Suppl 5):S449-S456. doi: 10.21037/tcr.2019.03.24.
6
Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation.
Cancers (Basel). 2021 Jul 4;13(13):3357. doi: 10.3390/cancers13133357.
7
HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells.
Cell Chem Biol. 2021 May 20;28(5):610-624.e5. doi: 10.1016/j.chembiol.2021.02.013. Epub 2021 Mar 11.
8
Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies.
Breast Care (Basel). 2020 Oct;15(5):470-480. doi: 10.1159/000510509. Epub 2020 Oct 7.
9
Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility.
Breast Cancer (Dove Med Press). 2020 Oct 14;12:153-163. doi: 10.2147/BCTT.S231502. eCollection 2020.
10
Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8 T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer.
Front Oncol. 2020 Sep 25;10:582863. doi: 10.3389/fonc.2020.582863. eCollection 2020.
本文引用的文献
1
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Oncoimmunology. 2015 Mar 2;4(4):e1008814. doi: 10.1080/2162402X.2015.1008814. eCollection 2015 Apr.
2
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
Oncotarget. 2015 May 30;6(15):13506-19. doi: 10.18632/oncotarget.3642.
3
Prognostic and predictive value of PDL1 expression in breast cancer.
Oncotarget. 2015 Mar 10;6(7):5449-64. doi: 10.18632/oncotarget.3216.
4
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
Breast Cancer Res Treat. 2014 Jul;146(1):15-24. doi: 10.1007/s10549-014-2988-5. Epub 2014 May 20.
5
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Clin Cancer Res. 2014 May 15;20(10):2773-82. doi: 10.1158/1078-0432.CCR-13-2702. Epub 2014 Mar 19.
6
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.
7
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
8
Kinome expression profiling and prognosis of basal breast cancers.
Mol Cancer. 2011 Jul 21;10:86. doi: 10.1186/1476-4598-10-86.
9
High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.
Int J Cancer. 2012 Jan 1;130(1):96-104. doi: 10.1002/ijc.25979.
Zotero 插件